Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Meyer

Showing results (461-470 of 510) with videos related to

Pageof 51
Sort By:
Neurology(R) Neuroimmunology & Neuroinflammation|September 18, 2025
Persons With Multiple Sclerosis Reveal Distinct Kynurenine Pathway Metabolite Patterns: A Multinational Cross-Sectional StudyMarie Kupjetz, Martin Langeskov-Christensen, Morten Riemenschneider, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 12, 2026
Persons With Multiple Sclerosis Reveal Distinct Kynurenine Pathway Metabolite Patterns: A Multinational Cross-Sectional StudyMarie Kupjetz, Martin Langeskov-Christensen, Morten Riemenschneider, et al.
The Lancet. Gastroenterology & Hepatology|June 27, 2017
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trialTim Meyer, Richard Fox, Yuk Ting Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2020
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular CarcinomaRichard S Finn, Masafumi Ikeda, Andrew X Zhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2019
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 TrialR Wendel Naumann, Antoine Hollebecque, Tim Meyer, et al.
Nature Communications|August 18, 2018
The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent mannerMette Ø Agerbæk, Sara R Bang-Christensen, Ming-Hsin Yang, et al.
The Lancet. Oncology|October 28, 2017
Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trialPiero Ferolla, Maria Pia Brizzi, Tim Meyer, et al.
ESMO Open|August 28, 2020
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trialRobin Kate Kelley, Baek-Yeol Ryoo, Philippe Merle, et al.
British Journal of Sports Medicine|May 27, 2022
International Olympic Committee (IOC) consensus statement on acute respiratory illness in athletes part 2: non-infective acute respiratory illnessMartin Schwellnus, Paolo Emilio Adami, Valerie Bougault, et al.
Nature Communications|June 7, 2022
Author Correction: The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent mannerMette Ø Agerbæk, Sara R Bang-Christensen, Ming-Hsin Yang, et al.
Pageof 51

Showing results (461-470 of 510) with videos related to

Sort By:
Pageof 51
Neurology(R) Neuroimmunology & Neuroinflammation|September 18, 2025
Persons With Multiple Sclerosis Reveal Distinct Kynurenine Pathway Metabolite Patterns: A Multinational Cross-Sectional StudyMarie Kupjetz, Martin Langeskov-Christensen, Morten Riemenschneider, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 12, 2026
Persons With Multiple Sclerosis Reveal Distinct Kynurenine Pathway Metabolite Patterns: A Multinational Cross-Sectional StudyMarie Kupjetz, Martin Langeskov-Christensen, Morten Riemenschneider, et al.
The Lancet. Gastroenterology & Hepatology|June 27, 2017
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trialTim Meyer, Richard Fox, Yuk Ting Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2020
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular CarcinomaRichard S Finn, Masafumi Ikeda, Andrew X Zhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2019
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 TrialR Wendel Naumann, Antoine Hollebecque, Tim Meyer, et al.
Nature Communications|August 18, 2018
The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent mannerMette Ø Agerbæk, Sara R Bang-Christensen, Ming-Hsin Yang, et al.
The Lancet. Oncology|October 28, 2017
Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trialPiero Ferolla, Maria Pia Brizzi, Tim Meyer, et al.
ESMO Open|August 28, 2020
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trialRobin Kate Kelley, Baek-Yeol Ryoo, Philippe Merle, et al.
British Journal of Sports Medicine|May 27, 2022
International Olympic Committee (IOC) consensus statement on acute respiratory illness in athletes part 2: non-infective acute respiratory illnessMartin Schwellnus, Paolo Emilio Adami, Valerie Bougault, et al.
Nature Communications|June 7, 2022
Author Correction: The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent mannerMette Ø Agerbæk, Sara R Bang-Christensen, Ming-Hsin Yang, et al.
Pageof 51